These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Studies on cefotaxime (HR 756) concentration in human biliary tract and clinical effect for acute or subacute cholecystitis with cholelithiasis (author's transl)].
    Author: Kasai Y, Nakanishi M, Sawada Y, Nakamura T, Hashimoto I, Mikami J, Bekki E, Hirasawa S, Abe H, Kasai K, Omosu M.
    Journal: Jpn J Antibiot; 1981 Mar; 34(3):447-52. PubMed ID: 6270392.
    Abstract:
    A new antibiotic drug of cephalosporin with marked resistance to beta-lactamase, cefotaxime (HR 756) for parenteral use in 8 patients with acute or subacute cholecystitis with cholelithiasis. Cefotaxime was administrated by intravenous injection or drip infusion at a daily dose of 1-4 g. Clinical response was excellent in 1 case, good in 7 cases, and fair or poor was none. Clinical adverse effect was not recognized. Cefotaxime in a dose of 1 g was given intravenously during operation to those same 8 patients. Tissue specimens of different places were taken from removed organs. The materials of A-bile and B-bile were subsequently taken at intervals. Determination of cefotaxime concentration was performed according to the bioassay method with Micrococcus luteus ATCC 9341 strain. Cefotaxime concentrations in the A-bile increased gradually until 1 hour after the intravenous administration. Cefotaxime was observed in the B-bile through the gallbladder wall after the intravenous injection.
    [Abstract] [Full Text] [Related] [New Search]